NAGIOS: RODERIC FUNCIONANDO

Treatment patterns for metastatic colorectal cancer in Spain

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Treatment patterns for metastatic colorectal cancer in Spain

dc.contributor.author	Aranda, E.
dc.contributor.author	Polo, E.
dc.contributor.author	Camps Herrero, Carlos
dc.contributor.author	Carrato Mena, Alfredo
dc.contributor.author	Díaz-Rubio, E.
dc.contributor.author	Guillem, V.
dc.contributor.author	López, R.
dc.contributor.author	Antón, A.
dc.date.accessioned	2020-10-05T17:11:15Z
dc.date.available	2020-10-05T17:11:15Z
dc.date.issued	2020
dc.identifier.citation	Aranda, E. Polo, E. Camps Herrero, Carlos Carrato Mena, Alfredo Díaz-Rubio, E. Guillem, V. López, R. Antón, A. 2020 Treatment patterns for metastatic colorectal cancer in Spain Clinical & Translational Oncology
dc.identifier.uri	https://hdl.handle.net/10550/75740
dc.description.abstract	Abstract Purpose The primary aim of this retrospective study was to describe the treatment patterns according to the type of treatment received by patients with metastatic colorectal cancer (mCRC) in Spain. Methods This was a retrospective, observational, multicenter study performed by 33 sites throughout Spain that included consecutive patients aged 18 years or older who had received or were receiving treatment for mCRC. Results At the time of inclusion, of the 873 evaluable patients, 507 (58%) had received two lines, 235 (27%) had received three lines, 106 (12%) had received four lines, and the remaining patients had received up to ten lines. The most frequent chemotherapy schemes were the FOLFOX or CAPOX regimens (66%) for frst-line treatment, FOLFOX, CAPOX or FOLFIRI (70%) for second-line treatment, and FOLFOX, FOLFIRI or other fuoropyrimidine-based regimens for third- and fourth-line (over 60%) treatment. Sixty percent of patients received targeted therapy as part of their frst-line treatment, and this proportion increased up to approximately 70% of patients as part of the second-line of treatment. A relevant proportion of patients were treated with unknown KRAS, and especially the BRAF, mutation statuses. Conclusions This study reveals inconsistencies regarding adherence to the recommendations of the ESMO guidelines for the management of mCRC in Spain. Improved adherence to the standard practice described in such guidelines for the determination of RAS and BRAF mutation statuses and the use of targeted therapies in frst-line treatment should be considered to guarantee that patients can beneft from the best therapeutic approaches available. Keywords Colorectal cancer · Metastatic · Treatment patterns · KRAS/BRAF mutation status · Clinical practice guideline
dc.language.iso	eng
dc.relation.ispartof	Clinical & Translational Oncology, 2020
dc.subject	Càncer
dc.subject	Càncer Pacients
dc.title	Treatment patterns for metastatic colorectal cancer in Spain
dc.type	journal article	es_ES
dc.date.updated	2020-10-05T17:11:15Z
dc.identifier.doi	10.1007/s12094-019-02279-5
dc.identifier.idgrec	138900
dc.rights.accessRights	open access	es_ES